Standout Papers

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patient... 2008 2026 2014 2020 747
  1. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033 (2008)
    Charles D. Blanke, Cathryn Rankin et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 6 from Science/Nature 67 standout
Sub-graph 1 of 21

Citing Papers

Thyroid cancer
2023 Standout
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
2022 Standout
2 intermediate papers

Works of Michael Tanaka being referenced

Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy
2016
An Evaluation of Barriers to Accrual in the Era of Legislation Requiring Insurance Coverage of Cancer Clinical Trial Costs in California
2004
and 1 more

Author Peers

Author Last Decade Papers Cites
Michael Tanaka 568 748 169 611 21 1.8k
Aliki Taylor 600 331 133 125 50 1.7k
Deborah S. Cohen 636 606 54 163 16 1.8k
Wakiko Ajiki 1196 854 252 115 64 2.6k
Patricia Stephenson 682 862 370 174 46 1.7k
Gauri Varadhachary 1527 658 339 92 25 2.1k
Juan C. Gutierrez 752 816 195 123 31 1.9k
Greer Gay 859 850 140 80 12 2.4k
L.M. Jost 639 498 212 283 39 1.6k
Denise K. Reinke 1131 1607 334 123 53 2.7k
Jerri Linn Phillips 1190 1035 398 302 31 2.7k

All Works

Loading papers...

Rankless by CCL
2026